Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Apr 12, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	0001750019-19-000021.pdf 0001750019-19-000021.rtf View HTML
Apr 12, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	0001750019-19-000025.pdf 0001750019-19-000025.rtf View HTML
Apr 12, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	0001750019-19-000023.pdf 0001750019-19-000023.rtf View HTML
Apr 12, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	0001750019-19-000024.pdf 0001750019-19-000024.rtf View HTML
Apr 12, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	0001750019-19-000026.pdf 0001750019-19-000026.rtf View HTML
Apr 12, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	0001750019-19-000027.pdf 0001750019-19-000027.rtf View HTML
May 13, 2019	Report of unscheduled material events or corporate event	8-K	Current Reports	0001750019-19-000035.pdf 0001750019-19-000035.rtf 0001750019-19-000035.xls View HTML
May 13, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001750019-19-000036.pdf 0001750019-19-000036.rtf 0001750019-19-000036.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT View HTML
Aug 08, 2019	Report of unscheduled material events or corporate event	8-K	Current Reports	0001750019-19-000044.pdf 0001750019-19-000044.rtf 0001750019-19-000044.xls View HTML
Aug 09, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001750019-19-000046.pdf 0001750019-19-000046.rtf 0001750019-19-000046.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.